Central nervous system manifestations in systemic lupus erythematosus

Current Rheumatology Reviews

Volumn 3, Issue 3, 2007, Pages 205-214

  Appenzeller, Simone ^a   Costallat, Lilian Tereza Lavras ^a   Cendes, Fernando ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

CNS involvement; SLE

Indexed keywords

ANTICOAGULANT AGENT; AUTOANTIBODY; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ILOPROST; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; PREDNISOLONE; PREDNISONE; RITUXIMAB;

ASEPTIC MENINGITIS; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; HUMAN; IMMUNOPATHOGENESIS; INCONTINENCE; LOW DRUG DOSE; MYELITIS; NERVOUS SYSTEM INJURY; NEUROIMAGING; NONHUMAN; PLASMAPHERESIS; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PSYCHOSIS; RAYNAUD PHENOMENON; REVIEW; SEIZURE; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR DISEASE;

EID: 34548301097     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339707781387572     Document Type: Review

References (137)

1. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994; 20: 129-158.
2. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732-741.
3. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968; 47: 337-369.
4. Hanly JG. Neuropsychiatric lupus. Rheum Dis Clin North Am 2005; 31: 273-98.
5. Kozora E, Arciniegas DB, Filley CM, et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 2005; 18: 159-62.
6. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
7. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
8. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001; 45: 419-423.
9. Ainiala H, Loukkola J, Peltola J, Korpela M, Hietaharju A. The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 2001; 5: 496-500.
10. Brey RL, Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 2002; 58: 1214-1220.
11. Afeltra A, Garzia P, Mitterhofer AP, et al. Neuropsychiatric lupus syndromes: relationship with antiphospholipid antibodies. Neurology 2003; 61: 108-10.
12. Hanly JG, Fisk JD, McCurdy G, Fougere L, Douglas JA. Neuropsychiatric syndromes in patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2005; 32: 1459-6.
13. Sanna G, Bertolaccini ML, Cuadrado MJ, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol 2003; 30: 985-92.
14. Mok CC, Lau CS, Wong RW. Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 766-71.
15. Hanly JG, McCurdy G, Fougere L, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance, J Rheumatol 2004; 31: 2156-2162.
16. Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology (Oxford). 2004; 43: 1555-60
17. Robert M, Sunitha R, Thulaseedharan NK. Neuropsychiatric manifestations systemic lupus erythematosus: a study from South India. Neurol India 2006; 54: 75-7.
18. Shimojima Y, Matsuda M, Gono T, Ishii W, Ikeda S. Relationship between clinical factors and neuropsychiatric manifestations in systemic lupus erythematosus. Clin Rheumatol 2005; 24: 469-75
19. Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 1971; 50: 85-95.
20. Feng PH, Cheah PS, Lee YK. Mortality in systemic lupus erythematosus: a 10-year review. Br Med J 1973; 4(5895): 772-4.
21. Cheatum DE, Hurd ER, Strunk SW, Ziff M. Renal histology and clinical course of systemic lupus erythematosus. A prospective study. Arthritis Rheum 1973; 16: 670-6.
22. Lee P, Urowitz MB, Bookman AA, et al. Systemic lupus erythematosus. A review of 110 cases with reference to nephritis, the nervous system, infections, aseptic necrosis and prognosis. Q J Med 1977; 46: 1-32.
23. Ginzler EM, Diamond HS, Weiner M, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 1982; 25: 601-611
24. Sibley JT, Olszynski WP, Decoteau WE, Sundaram MB. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol 1992; 19: 47-52.
25. Sergent JS, Lockshin MD, Klempner MS, Lipsky BA. Central nervous system disease in systemic lupus erythematosus. Therapy and prognosis. Am J Med 1975; 58: 644-54.
26. Feinglass EJ, Arnett FC, Dorsch CA, Zizic TM, Stevens MB. Neuropsychiatric manifestations of systemic lupus erythematosus: diagnosis, clinical spectrum, and relationship to other features of the disease. Medicine (Baltimore) 1976; 55: 323-39.
27. Kovacs JA, Urowitz MB, Gladman DD. Dilemmas in neuropsychiatric lupus. Rheum Dis Clin North Am 1993; 19: 795-814.
28. Jonsen A, Bengston AA, Nived O, Rayberg B, Sturfelt G. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology 2002; 41: 1308-12.
29. Carlomagno S, Migliaresi S, Ambrosone L, Sannino M, Sanges G, Di Iorio G. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol 2000; 247: 273-9.
30. Karassa FB, Ioannidis JP, Boki KA, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med 2000; 109: 628-34.
31. Appenzeller S, Carnevalle AD, Li LM, Costallat LT, Cendes F. Hippocampal atrophy in Systemic lupus erythematosus. Ann Rheum Dis 2006; 65: 1585-9.
32. Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1994; 2: 1825-1831
33. Hay EM, Huddy A, Black D, et al. A prospective study of psychiatric disorder and cognitive function in systemic lupus erythematosus. Ann Rheum Dis 1994; 53: 298-303
34. Waterloo K, Omdal R, Husby G, Mellgren SI. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology (Oxford) 2002; 41: 411-415.
35. Brooks WK Jung RE, Ford CC, et al. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999; 26: 81-85
36. Appenzeller S, Li LM, Costallat LT, Cendes F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 2005; 128: 2933-40.
37. Hanly JG, Harrison MJ. Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 2005; 19: 799-821.
38. Devinsky O, Petito CK, Alonso DR. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura. Ann Neurol 1988; 23: 380-384.
39. Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955-1977. Sem Arthritis Rheum 1979; 8: 212-221.
40. Zvaifler NJ, Bludstein HG. The pathogenesis of central nervous system manifestations of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 862-866.
41. Johnson RT, Richardson EP. The neurological manifestations of systemic lupus erythematosus. Medicine (Baltimore) 1968; 47: 337-69
42. Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus 2003; 12: 908-15.
43. Karpiak SE, Graf L, Rapport MM. Antiserum to brain gangliosides produces recurrent epileptiform activity. Science 1976; 194: 735-7.
44. Kobiler D, Allweis C. The effect of antisynaptosomal plasma membrane antibodies on memory. Brain Res 1976; 115: 129-38.
45. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an Nmethyl- D-aspartate receptor antagonist, AP5. Nature 1986; 319: 774-776.
46. Akbarian S, Sucher NJ, Bradley D, et al. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 1996; 16: 19-30.
47. Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 1994; 37: 307-315.
48. Arnett FC, Reveille JD, Moutsopoulos HM, Georgescu L, Elkon KB. Ribosomal P autoantibodies in systemic lupus erythematosus. Frequencies in different ethnic groups and clinical and immunogenetic associations. Arthritis Rheum 1996; 39: 1833-1839.
49. Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317: 265-271.
50. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of antiribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54: 312-24.
51. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E. et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease. Ann Rheum Dis 2000; 59: 99-104.
52. Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41: 1357-1366.
53. Hanly JG. Antiphospholipid syndrome: an overview. CMAJ 2003; 168: 1675-1682.
54. Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus reythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41: 1357-66.
55. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698.
56. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 735-741.
57. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD, Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 1999; 8: 127-133.
58. Appenzeller S, Zeller CB, Annichino-Bizzachi JM, et al. Cerebral venous thrombosis: influence of risk factors and imaging findings on prognosis. Clinical Neurol and Neurourg 2005; 107: 371-378.
59. Conti F, Alessandri C, Bompane D, et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for antiendothelial-cell Abs. Arthritis Res Ther 2004; 6: R366-72.
60. Song J, Park YB, Lee WK, Lee KH, Lee SK. Clinical associations of anti-endothelial cell Abs in patients with systemic lupus erythematosus. Rheumatol Int 2000; 20: 1-7.
61. Schenatto CB, Xavier RM, Bredemeier M, et al. Raised serum S100B protein levels in neuropsychiatric lupus. Ann Rheum Dis 2006; 65: 829-31.
62. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33: 644-649.
63. Jara LJ, Irigoyen L, Ortiz MJ, Zazueta B, Bravo G, Espinoza LR. Prolactin and interleukin-6 in neuropsychiatric lupus erythematosus. Clin Rheumatol 1998; 17: 110-114.
64. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus crythematosus with central nervous system involvement. Lupus 2000; 9: 498-503.
65. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992; 35: 417-422.
66. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127: 393-398.
67. Ainiala H, Hietaharju A, Dastidar P, et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004; 50: 858-65.
68. Small P, Mass MF, Kohler PF, Harbeck RJ. Central nervous system involvement in SLE. Diagnostic profile and clinical features. Arthritis Rheum 1977; 20: 869-878.
69. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881-2887.
70. Appenzeller S, Rondina JM, Li LM, Costallat LT, Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 2783-9.
71. McCune WJ, MacGuirre A, Aisen A, Gebarski S. Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance scanning. Arthritis Rheum 1988, 31, 159-166
72. Rovaris M, Viti B, Ciboddo G, et al. Brain involvement in systemic immune mediated diseases: magnetic resonance and magnetisation transfer imaging study. J Neurol Neurosurg Psychiatry 2000; 68: 170-7.
73. Sibbitt WL Jr, Schmidt PJ, Hart BL, Brooks WM. Fluid attenuated inversion recovery (FLAIR) imaging in neuropsychiatric systemic lupus erythematosus. J Rheumatol 2003; 30: 1983-9.
74. Cotton F, Bouffard-Vercelli J, Hermier M, et al. MRI of central nervous system in a series of 58 systemic lupus crythematosus (SLE) patients with or without overt neuropsychiatric manifestations. Rev Med Interne 2004; 25: 8-15.
75. Peterson PL, Howe FA, Clark CA, Axford JS. Quantitative magnetic resonance imaging in neuropsychistric systemic lupus erythematosus. Lupus 2003; 12: 897-902.
76. Graham JW, Jan W. MRI and the brain in systemic lupus erythematosus. Lupus 2003; 12: 891-6.
77. Csepany T, Bereczki D, Kollar J, Sikula J, Kiss E, Csiba L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 2003; 250: 1348-54.
78. Jennings JE, Sundgren PC, Attwood J, McCune J, Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 2004; 46: 15-21.
79. Oku K, Atsumi T, Furukawa S, et al. Cerebral imaging by magnetic resonance imaging and single photon emission computed tomography in systemic lupus erythematosus with central nervous system involvement. Rheumatology (Oxford) 2003; 12: 773-7.
80. Holliday SL, Navarrete MG, Hermosillo-Romo D, Valdez CR, Saklad AR, Escalante A, Brey RL. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003; 12: 697-703.
81. Steens SC, Admiraal-Behloul F, Bosma GP, et al. Selective gray matter damage in neuropsychiatric lupus. Arthritis Rheum 2004; 50: 2877-81.
82. Vermeer SE, Priens ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MB. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003; 348:1215-1222.
83. Bosma GP, Rood MJ, Huizinga TW, do Jong BA, Bollen EL, van Buchem MA. Detection of cerebral involvement in patients with active neuropsychiatric systemic lupus erythematosus by the use of volumetric magnetization transfer imaging. Arthritis Rheum 2000; 43: 2428-36.
84. Bosma GP, Rood MJ, Zwinderman AH, Huizinga TW, van Buchem MA. Evidence of central nervous system damage in patients with neuropsychiatric systemic lupus erythematosus, demonstrated by magnetization transfer imaging. Arthritis Rheum 2000; 43: 48-54.
85. Moritani T, Shrier DA, Numaguchi Y, et al. Diffusion-weighted echo-planar MR imaging of CNS involvement in systemic lupus erythematosus. Acad Radiol 2001; 8: 741-53.
86. Demaerel P, De Ruyter N, Maes F, Velghe B, Wilms G. Magnetic resonance angiography in suspected cerebral vasculitis. Eur Radiol 2004; 14: 1005-12.
87. Hanly JG. Single photon emission computed tomography scanning in neuropsychiatric systemic lupus erythematosus. J Rheumatol 1998; 25: 401-3.
88. Nossent JC, Hovestadt A, Schonfeld DH, Swaak AJ. Single photon-emission computed tomography of the brain in the evaluation of cerebral lupus. Arthritis Rheum 1991; 34: 1397-403.
89. Rubbert A, Marienhagen J, Pirner K, et al. Single-photon emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1253-62.
90. Rogers MP, Waterhouse E, Negel JS, et al. 1-13 iofetamine SPECT scan in systemic lupus erythematousus with cognitive and other minor neuropsychiatric symptoms: a pilot study. Lupus, 1992; 215-219.
91. Kovacs JA, Urowitz MB, Gjadman DD, Zeman R. The use of single photon emission computerized tomography in neguropsychiatric SLE: a pilot study. J Rheumatol 1995; 22: 1247-53.
92. Sabet A, Sibbitt WL Jr, Stidley CA, Danska J, Brooks WM. Neurometabolite markers of cerebral injury in die antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998; 29: 2254-60.
93. de Certaines JD, Bovee WMMJ, Podo F. Magnetic resonance spectroscopy in biology and medicine: functional and pathological tissue characterization. New York: Pergamon Press, 1992.
94. Rudkin TM, Arnold DL. Proton magnetic resonance spectroscopy for the diagnosis and management of cerebral disorders. Arch Neurol 1999; 56: 919-26.
95. Denburg SD, Carbotte RM, Denburg JA. Corticosteroids and neuropsychological functioning in patients with systemic lupus erythematosus. Arthritis Rheum 1994; 37: 1311-1320.
96. Barile L, Lavalle C. Transverse myelitis in systemic lupus erythematosus - the effect of IV pulse methylprednisolone and cyclophosphamide. J Rheumatol 1992; 19: 370-372.
97. Eyanson S, Passo MH, Aldo-Benson MA, Benson MD. Methylprednisolone pulse therapy for nonrenal lupus erythematosus. Ann Rheum Dis 1980; 39: 377-380.
98. Mok CC, Lau CS, Wong RW. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study. Am J Med 2003; 115: 59-62.
99. Barile-Fabris L, Ariza-Andraca R, Olguin-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 620-5.
100. Leung FK, Fortin PR. Intravenous cyclophosphamide and high dose corticosteroids improve MRI lesions in demyelinating syndrome in systemic lupus erythematosus. J Rheumatol 2003; 30: 1871-1873.
101. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81(296): 975-984.
102. Neuwelt CM, Lacks S, Kaye BF, Ellman JB, Borenstein DG. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995; 98: 32-41.
103. Ramos PC, Mendez MJ, Ames PR, Khamashta MA, Hughes GR. Pulse cyclophosphamide in the treatment of neumpsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996; 14: 295-299.
104. Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 1998; 25: 467-473.
105. Galindo-Rodriguez G, Avina-Zubieta JA, Pizarro S, et al. Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial. Am J Med 1999; 106: 65-69.
106. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988; 318: 1423-1431.
107. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
108. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
109. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GRV. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore) 2000; 79: 57-68.
110. Sanna G, Bertolaccini ML, Mathieu A. Central nervous system lupus: a clinical approach to theraphy. Lupus 2003; 12: 935-942.
111. Baca V, Lavalle C, Garcia R, et al. Favorable responce to intravenous methylpronisolone and cyclophospharride in children with severe neuropsychiatric lupus. J Rheumatol 1999; 26: 432-439.
112. Harisdangkul V, Doorenbos D, Subramony SH. Lupus transverse myelopathy: better outcome with early recognition and aggressive highdose-intravenous corticosteroid pulse treatment. J Neurol 1995; 242: 326-331.
113. Chatham WW, Kimberley RP. Treatment of lupus with corticoster oids. Lupus 2001; 10: 140-147.
114. Funauohi M, Ohno M, Nozaki Y, Sugiyama M, Kinoshita K, Kanamaru A. Intrathecal corticosteroids for systemic lupus erythematosus with central nervous system involvement. J Rheumatol 2003; 30: 207-208.
115. Propper DJ, Bucknall RC. Acute transverse myelopathy complicating systemic lupus erythematosus. Ann Rheum Dis 1989; 48: 512-515.
116. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991; 81: 975-984.
117. Takada K, Illei GG, Boumpas DT. Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001; 10: 154-161.
118. Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2000: CD002265.
119. Sakic B, Kolb B, Whishaw IQ, Gorny G, Szechtman H, Denburg JA. Immunosuppression prevents neuronal atrophy in lupus-prone mice: evidence for brain damage induced by autoinimune disease? J Neuroimmunol 2000; 111: 93-101.
120. Farrell M, Sakic B, Szechtman H, Denburg JA. Effect of cyclophosphamide on leukocytic in Itration in the brain ofMRL/1pr mice. Lupus 1997; 6: 268-274.
121. Sakic B. Szechtman H, Denburg SD, Denburg JA. Immunosuppressive treatment prevents behavioral de. cit in autoimmune MRL-1pr mice. Physiol Behav 1995; 58: 797-802.
122. Schroeder JO, Euler HH. Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus. Adv Exp Med Biol 1989; 260: 203-213.
123. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
124. Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. Cochrane Database Syst Rev 2001: CD002063.
125. Sherer Y, Levy Y. Langevitz P, Lorber M, Fabrizzi F, Shoenfeld Y. Successful treatment of systemic lupus erythematosus cerebritis with intravenous immunoglobulin. Clin Rheumatol 1999; 18: 170-173.
126. Tomer Y, Shoenfeld Y. Successful treatment of psychosis secondary to SLE with high dose intravenous immunoglobulin. Clin Exp Rheumatol 1992; 10: 391-393.
127. Valesini G, Priori R, Francia A, et al. Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate. Springer Semin Immunopathol 1994; 16: 313-321.
128. Dong Y, Zhang X, Tang F, Tian X, Zhao Y, Zhang F. Intrathecal injection with methotrexate plus dexamethasone in the treatment of central nervous system involvement in systemic lupus erythematosus. Chin Med J (Engl) 2001; 114: 764-766.
129. Hay EM. Psychiatric disorder and cognitive impairment in SLE. Lupus 1994; 3: 145-148.
130. Schantz V, Oestergaard LL, Junker P. Shrinking spinal cord following transverse myelopathy in a patient with systemic lupus erythematosus and the phospholipid antibody syndrome. J Rheumatol 1998; 25: 1425-1428.
131. Moore PM, Isenberg D. Therapy of neuro-psychiatric systemic lupus erythematosus. Rheumatol Europe 1997; 26: 36-39.
132. Grisanti M, Nader A, Cacciuttolo R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid syndrome: successful treatment with mycophenolate-mofetil. Lupus 2001; 10: S31.
133. Mathieu A, Sanna G, Mameli A et al. Sustained normalization of cerebral blood-flow after iloprost therapy in a patient with neuropsychiatric systemic lupus erythematosus. Lupus 2002; 11: 52-56.
134. Appenzeller S, Costallat LT. Clinical implications of migraine in systemic lupus erythematosus: relation to cumulative organ damage. Cephalalgia 2004; 24: 1024-30.
135. Appenzeller S, Cendes F, Costallat LT. Epileptic seizures in systemic lupus erythematosus. Neurology 2004; 63: 1808-12.
136. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic and phospholipid syndrome (Hughes syndrome). Lupus 2006; 15: 191-7.
137. D'Cruz DP, Mellor-Pita S, Joven B, et al. Transverse myelitis as the first manifestation of systemic lupus erythematosus or lupus-like disease: good functional outcome and relevance of antiphospholipid antibodies. J Rheumatol 2004; 31(2): 280-5.